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Abstract  
Oxidative stress is one of the cellular responses determined at early stages of toxicity 
and can be induced by many different classes of chemicals. The nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2) represents one of the key regulators of the 
Antioxidant-Response-Element-(ARE)-driven cellular defence mechanisms against 
oxidative stress. Nrf2 has been shown to have a cytoprotective, antioxidant and anti-
inflammatory role in virtually all cell types in the body, both under physiological and 
disease conditions, as it regulates the expression of enzymes involved in detoxification 
processes. The SCR&Tox consortium, part of the SEURAT-1 research initiative, 
established to investigate Nrf2 signaling activation in neuronal models derived from 
hiPSCs. Analysis of Nrf2 signaling activation could serve as a base for the establishment 
of a horizontal assay to assess oxidative stress induction. Neuronal and glial cells 
undergo oxidative stress as an early response to different classes of chemicals, including 
inhibitors of mitochondrial respiration, such as rotenone, which is known to inhibit 
complex I of the mitochondrial respiratory chain. Moreover, human induced pluripotent 
stem cells (hiPSCs) are currently regarded as a powerful tool for drug and chemical 
screening and development of new in vitro testing strategies in the field of toxicology, 
including neurotoxicity and developmental neurotoxicity evaluation.   
This technical report summarizes the strategy adopted by EURL-ECVAM to assess Nrf2 
signalling activation in neuronal models derived from hiPSCs. In particular, as agreed 
within the SCR&Tox consortium, two hiPSC-neuronal models were used: (i) an Nrf2-
Luciferase reporter neural stem cell model (called Clone 27 (Cl27), obtained from 
Phenocell, France), and (ii) a wild type IMR90-hiPSC-derived neuronal/glial model 
(obtained from I-Stem, France). The results obtained with the wild type (IMR90-hiPSC) 
neuronal model indicate that rotenone induces the activation of Nrf2 signaling, increases 
the number of astroglial cells and decreases the number of dopaminergic neurons. The 
obtained results suggest that hiPSC-derived mixed neuronal/glial culture could be a 
valuable in vitro model for the establishment of neuronal specific assays to evaluate Nrf2 
pathway activation (biomarker of oxidative stress) using neuronal specific readouts that 
could be applied to in vitro neurotoxicity evaluation.  
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1 Introduction 
In recent years (2011-2015), the European Union Reference Laboratory for Alternative 
to Animal Testing (EURL ECVAM) and the "Health, Chemicals Safety and Alternative 
Methods" Unit (former Systems Toxicology Unit) of the Joint Research Centre's 
Directorate F "Consumers and Reference Materials" (former Institute for Health and 
Consumer Protection) have been involved in the SEURAT-1 initiative (http://www.seurat-
1.eu/), aimed at developing knowledge and technology building blocks required for the 
development of solutions for the replacement, reduction or refinement (3Rs) of current 
repeated dose systemic toxicity testing in vivo used for the assessment of human safety. 
The SEURAT-1 research initiative was composed of six research projects (SCR&Tox, 
HeMiBio, DETECTIVE, COSMOS, NOTOX and ToxBank), coordinated and supported by a 
7th project (COACH). Among these projects, SCR&Tox (http://www.scrtox.eu/) aimed at 
making use of human pluripotent stem cell lines, in particular human induced pluripotent 
stem cells (hiPSCs) and their derivatives, to provide in vitro assays for predicting toxicity 
of pharmaceutical compounds and cosmetic ingredients.  
HiPSCs represent unique tools for toxicity screening and improving mechanistic 
understanding of chemically-induced adverse effects (Hou et al., 2013; Kumar et al., 
2012; Yap et al., 2015). HiPSCs have been identified as a potential source of various cell 
types for toxicity testing (Hou et al., 2013). HiPSCs share similar characteristics with 
human embryonic stem cells (hESCs) (Krueger et al., 2010; Pistollato et al., 2012), i.e. 
are characterized by unlimited self-renewal and capacity to generate different human 
tissue-specific somatic cells (Avior et al., 2016; Robinton and Daley, 2012), including 
neurons and glia. Moreover, these stem cell-based systems offer an innovative 
alternative for obtaining a large number of human cells, serving as a valuable tool for 
the development of in vitro models for toxicity testing (Avior et al., 2016), often 
applicable for high throughput screening (HTS) approaches (Desbordes and Studer, 
2013). 
Oxidative stress is one of the non-cell specific cellular responses determined at early 
stages of toxicity and induced by different classes of chemicals. Among the key 
regulators of the Antioxidant-Response-Element-(ARE)-driven cellular defence 
mechanisms against oxidative stress is the Nuclear factor (erythroid-derived 2)-like 2 
(Nrf2), which has a cytoprotective role in several diseases (Ramsey et al., 2007). Under 
normal (unstressed) conditions, Nrf2 is kept in the cytoplasm by Kelch like-ECH-
associated protein 1 (Keap1) and Cullin 3, which degrade Nrf2 by ubiquitination (Sun et 
al., 2007). Under oxidative/electrophilic stress, cysteine residues in Keap1 get disrupted, 
Nrf2 travels to the nucleus, binds to the antioxidant response element (ARE) in the 
upstream promoter region of many antioxidative genes (e.g., NQO1, SRXN1, GSR, 
HMOX1) that support detoxification processes that take place in many 
neurodegenerative diseases (Ramsey et al., 2007). Within the SCR&Tox consortium, it 
was decided to assess Nrf2 signaling activation in neuronal models derived from hiPSCs. 
Analysis of Nrf2 signaling activation could serve as a base for the establishment of a 
horizontal assay, relevant to different organ toxicity, permitting assessment of oxidative 
stress induction.  
In our studies we exposed cells to rotenone that is a specific inhibitor of mitochondrial 
complex I, triggering oxidative stress (positive control). Rotenone is a crystalline 
isoflavone (Figure 1) used as a broad-spectrum insecticide, piscicide, and pesticide, 
occurring naturally in the seeds and stems of several plants, such as the jicama vine 
plant and the roots of several members of Fabaceae.  
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Figure 1. Skeletal formula of rotenone 
 
It is classified as moderately hazardous by the World Health Organization1. Rotenone 
works by inhibiting the transfer of electrons from iron-sulfur centres in complex I to 
ubiquinone in the mitochondrial respiratory chain. This creates a back-up of electrons 
within the mitochondrial matrix, causing reduction of cellular oxygen and the generation 
of reactive oxygen species (ROS). Rotenone has been shown to cause oxidative stress 
triggering the translocation of Nrf2 from the cytoplasm into the nucleus, followed by 
induction of the Nrf2-ARE target gene transcription (Tufekci et al., 2011). 
Importantly, environmental exposure to rotenone has been shown to be linked to an 
increase risk of Parkinson's disease (PD) and PD-like neuropathology, as shown by 
several human epidemiological studies (Nandipati and Litvan, 2016). 
This technical report summarizes the strategy adopted by EURL-ECVAM to assess Nrf2 
signalling activation in neuronal models derived from hiPSCs and the main results. To 
assess the effects of rotenone on Nrf2 pathway activation, two hiPSC-neuronal models 
were adopted: a Nrf2-Luciferase reporter neural stem cell model (Cl27, obtained from 
Phenocell, France, one of the partners contributing to the SCR&Tox project), and a wild 
type IMR90-hiPSC-derived neuronal/glial model (kindly provided by Dr. Marc Peschanski 
(Coordinator of SCR&Tox), I-Stem, France).  
Overall our results suggest that hiPSC-derived mixed neuronal/glial culture could be a 
valuable in vitro model for the establishment of an assay for evaluation of Nrf2 pathway 
activation (a biomarker of oxidative stress) combined with other test methods for 
perturbation of neuronal-specific pathways, which could be applied to assess 
neurotoxicity in vitro. 
 
 
2 Methodological approach   
Rotenone was used to assess the activation of the Nrf2 pathway in mixed cultures of 
neuronal and glial cells differentiated from hiPSC-derived neural stem cells (NSCs). In 
particular two different cellular models have been used: an Nrf2-Luciferase reporter NSC 
model (called Cl27, obtained from Phenocell, France), and a wild type IMR90-hiPSC-
derived neuronal/glial model (obtained from I-Stem, France). The maintenance and 
differentiation protocols applied for Cl27 were the ones specified by the supplier 
(PhenoCell), while maintenance, expansion and differentiation protocols for IMR90-
hiPSCs were developed and optimized in house and are available at https://ecvam-
dbalm.jrc.ec.europa.eu/beta/index.cfm/methodsAndProtocols/index.  
                                           
1 IPCS, International Programme on Chemical Safety; United Nations Environment Programme; International 
Labour Organization; World Health Organization. (2007). The WHO Recommended Classification of Pesticides 
by Hazard. World Health Organization. ISBN 92-4-154663-8. Retrieved 2007-12-02. 
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A more detailed description of the cellular models and the readouts used to assess the 
effects of rotenone on Nrf2 pathway activation and on neuronal and glia-related 
endpoints are described in the next sections.  
 
2.1 The cellular models: human induced pluripotent stem cell 
(hiPSC)-derived neuronal and glial cultures 
2.1.1 Nrf2-Luciferase reporter (NSC) model (Clone 27) 
An Nrf2-Luciferase reporter NSC model (named clone 27 (Cl27)) was created by 
Phenocell (http://phenocell.fr/), as part of the activities related to the SCR&Tox 
consortium, by transducing an Nrf2-Luciferase construct in NSCs derived from PC1429-
hiPSCs (details about the transduction method can be obtained from PhenoCell). Cells 
were expanded and subcultured as indicated by manufacturer. The medium used for 
NSC expansion was composed of: 50% Neurobasal medium, 50% DMEM-F12 medium 
(with GlutaMax), B27 supplements (without retinol), N2 supplements, Beta-
mercaptoethanol (50 µM), and adding basic fibroblast growth factor (bFGF) (10 ng/ml), 
epidermal growth factor (EGF) (10 ng/ml) and brain derived neurotrophic factor (BDNF) 
(20 ng/ml) (all from ThermoFisher). Cl27 cells were differentiated for 21 days as 
recommended by Phenocell using the same medium formulation, plus BDNF (20 ng/ml), 
but withdrawing bFGF and EGF. 
Cells were treated for either 24 or 72 hr with 1, 10, 100, 500 and 2500 nM rotenone 
(Sigma-Aldrich, dissolved in DMSO) at various differentiation stages (i.e., differentiation 
days 5, 12 and 19), accounting for solvent control analysis. Analysis of cytotoxicity (by 
Alamar blue test) and Nrf2/luciferase activity were assessed by means of a plate reader 
(Tecan) after 24 and 72 hr treatment. Further immunostaining and qPCR analyses were 
conducted to assess the phenotypic identity of the differentiated cells. 
 
2.1.2 Wild type hiPSC-IMR90-derived neuronal/glial cells  
IMR90-hiPSCs were kindly provided by Dr. Marc Peschanski (I-Stem, France). IMR90 
fibroblast cell line was established on 07/07/1975 using explants of minced lung tissue 
obtained from a clinically normal 16 week old fetus and they exhibit a normal female 
karyotype (46, XX)2. IMR90 fibroblasts were reprogrammed into hiPSCs at I-Stem by 
viral transduction of Oct4 and Sox2 by using the pMIG vectors (Addgene). 
hiPSCs were cultured, under feeder-free conditions, on matrigel™ hESC-qualified matrix 
(Corning) pre-coated Petri-dishes in the presence of mTeSR™1 medium containing 
mTeSR™1 5X supplements (Stem Cell Technologies) prepared following manufacturer's 
instructions. HiPSC colonies were passaged by micro-dissection using a 30G needle.  
IMR90-hiPSCs were differentiated toward neurons and glia following a protocol described 
in https://ecvam-dbalm.jrc.ec.europa.eu/beta/index.cfm/methodsAndProtocols/index, 
which is a modified version of the method described by Pistollato et al. (Pistollato et al., 
2014). Briefly, IMR90-derived colonies cultured on matrigel™ hESC-qualified matrix 
(Corning) coated dishes were manually microdissected into 200 µm x 200 µm fragments 
using a 30G needle. For the generation of embryoid bodies (EBs), fragments were 
transferred into a low attachment Petri-dish (Greiner) and cultures in EB medium. After 
48 hours, generated EBs were plated on laminin (Sigma-Aldrich)-coated dishes and 
cultured in neuroepithelial induction (NRI) medium for further 7 days. On day 8, 
neuroepithelial aggregates (rosettes) were visible and were cut in fragments using a 30G 
needle under a phase contrast microscope. Then, rosettes were spun down, resuspended 
                                           
2 https://catalog.coriell.org/  
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in 1 ml of phosphate-buffered saline (PBS, 1X) and partially dissociated using a p1000 
tip. Finally, dissociated rosettes were plated on laminin-coated dishes and cultured in the 
presence of neural differentiation (ND) medium for 3 weeks.  
A protocol for the expansion of rosette-derived neural stem cells (NSCs) was developed 
(https://ecvam-dbalm.jrc.ec.europa.eu/beta/index.cfm/methodsAndProtocols/index). 
Briefly, rosette-derived NSCs were passaged by enzymatic dissociation using 0.05% 
Trypsin-EDTA (ThermoFisher), and replated on matrigel® basement membrane matrix 
(Corning) coated dishes in the presence of neural induction (NI) medium (50,000 
cells/cm2). NI medium was refreshed every other day. At early passages (1-4), a cell 
plating density of ~ 75x104 cells/cm2 was applied to improve cell viability after 
passaging. NSCs were differentiated into neuronal mixed cultures using ND medium as 
described above. On differentiation day 21, cells were treated for 24 hr with 1, 10, 100 
nM rotenone (Sigma-Aldrich, dissolved in DMSO), accounting for solvent control analysis. 
For detailed information about the different media used for expansion and differentiation 
of NSCs, refer to recently published manuscript from Zagoura D. et al. (Zagoura D et al. 
2016) and the EURL ECVAM DBALM website https://ecvam-
dbalm.jrc.ec.europa.eu/methods-and-protocols/protocol/standard-operating-procedure-
for-differentiation-of-human-induced-pluripotent-stem-cells-into-post-mitotic-neurons-
and-glial-cells-%28mixed-culture%29-protocol-no.-165/key/p_1570 and https://ecvam-
dbalm.jrc.ec.europa.eu/methods-and-protocols/protocol/standard-operating-procedure-
for-expansion-of-rosette-derived-neural-stem-cells-protocol-no.-166/key/p_1571. A 24 
hr treatment with 10 µM and 100 µM hydrogen peroxide (H2O2, Sigma-Aldrich) was 
used as a positive control for induction of oxidative stress and activation of the Nrf2 
pathway. 
 
2.2 Readouts applied to assess rotenone effects 
Assessment of rotenone effects was assessed by performing the analyses described in 
the following sections.  
 
2.2.1 Alamar blue (resazurin) for analysis of cell viability  
Cl27 cells were exposed to different concentrations of rotenone (ranging from 1 nM to 
2500 nM) for 72 hr to determine possible cytotoxic effects. To this end, the medium 
containing rotenone was removed and the cells were incubated with 10 μM resazurin 
(ThermoFisher), diluted in ND medium in the incubator (37°C, 5% CO2) for 2 hr. 
Resazurin is the active ingredient of alamar blue reagent which upon entering live cells 
gets converted to resorufin that is red and highly fluorescent, and its absorbance can be 
read on a spectrophotometer. The fluorescence of the reagent wαs measured at 530-560 
nm-/590 nm (excitation/emission) in a multiwell fluorimetric reader (Tecan). The results 
were normalized to the mean of solvent treated cells (0.1% DMSO). 
 
2.2.2 Immunocytochemistry and high content imaging (HCI) 
About 6000-7000 cells/well in 96 well plates were plated and differentiated for 21 days. 
On day 21 cells were treated with either rotenone or H2O2 as described above, and after 
24 hr cells were fixed with cold 4% paraformaldehyde, washed in PBS 1X, permeabilized 
in PBS 1X containing 0.1% Triton-X-100 and 3% bovine serum albumin (BSA) for 15 
minutes at room temperature, and further incubated with 3% BSA/1X PBS (blocking 
solution) to prevent nonspecific binding of the antibodies. The cells were then incubated 
with primary antibodies as follows: neurofilament 200 (NF200, rabbit, 1:1000, Sigma-
Aldrich), glial fibrillary acidic protein (GFAP, mouse, 1:500, Merck-Millipore), 
microtubule-associated protein-2 (MAP2, mouse, 1:500, Sigma-Aldrich), synaptophysin 
(SYN, rabbit, 1:200, Abcam), Nrf2 (rabbit), Keap1 (rabbit), sulfiredoxin1 (SRXN1, 
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goat),NAD(P)H quinone oxidoreductase 1 (NQO1, goat) (all 1:200, Abcam), nestin 
(rabbit, 1:200, Sigma-Aldrich), Oct4 (mouse, 1:100, Millipore), Sox2 (rabbit, 1:200, 
Millipore), tyrosine hydroxylase (TH, rabbit, 1:200, Millipore), gamma-aminobutyric acid 
(GABA, mouse, 1:100, Sigma-Aldrich), vesicular glutamate transporter 1 (VGlut1, rabbit, 
1:500, Abcam) in blocking solution overnight at 4°C. The cells were washed with PBS 
and further incubated with fluorochrome-conjugated secondary antibodies (1:1000, 
Invitrogen). Nuclei were counterstained with DAPI dye (0.3µM, Sigma-Aldrich). 
Quantification of mean fluorescence intensity and of the relative percentages of cell 
types was performed using two specific ArrayScan algorithms: Cytotoxicity V.4 and 
NucTrans V.4 bioapplications. Both the applications apply a specific nuclear mask around 
the DAPI staining defined according to nuclear morphology, discarding invalid nuclei 
(i.e., nuclei that were pyknotic, bright and/or dense clumps of cells) and, on the valid 
nuclei (i.e., homogenous round-shaped nuclei, indicative of live cells) an additional cell 
body shape mask was applied according to the type of antibody/antigen staining, as 
already described (O'Brien et al., 2006). The NucTrans V.4 algorithm calculates the level 
of fluorescence intensity both in the nucleus and the cytoplasm, applying respectively a 
circular mask (for nuclear signal) and a ring shape mask (for cytoplasmic signal). 
Secondary antibody incubation alone was used to determine the intensity level of 
fluorescent background that was subtracted. The ArrayScan™ XTI High Content Platform 
was set up to take a minimum of 20 pictures/well. Each staining was done on 7-8 
internal replicates for each condition. 
 
2.2.3 Quantitative real-time PCR (qPCR) 
Analysis of gene expression by qPCR was performed on differentiated and rotenone-
treated (i.e., 1-10-100 nM) and untreated (control) cells. RNA was isolated using the 
RNAqueous®-Micro Kit (ThermoFisher) according to manufacturer's instructions, and 
500 ng of total RNA was reverse transcribed using the High Capacity cDNA Reverse 
Transcription Kit (as directed, ThermoFisher). qPCR reactions were run in duplicate using 
TaqMan® Gene Expression Master Mix (ThermoFisher) and the following TaqMan gene 
expression assays (all from ThermoFisher): NCAM1 (Hs00941830_m1), GFAP 
(Hs00909233_m1), MAP2 (Hs00258900_m1), NQO1 (Hs02512143_s1), SRXN1 
(Hs00607800_m1), HMOX1 (Hs01110250_m1), GSR (Hs00167317_m1), PAX6 
(Hs01088112_m1), NES (Hs00707120_s1), SOX1 (Hs01057642_s1), GRIA1 
(Hs00181348_m1), GAP43 (Hs00967138_m1), GABRA3 (Hs00968132_m1), GABRA1 
(Hs00168058_m1), NR4A2 (Hs00428691_m1), TH (Hs00165941_m1), GAPDH 
(Hs02758991_g1), ACTB (Hs99999903_m1). Fluorescent emission was recorded in real-
time using the ABI PRISM Sequence Detection System 7900HT (Applied Biosystems). 
PCR amplification conditions consisted of 45 cycles with primers annealing at 60°C. 
Relative RNA quantities were normalized to the reference genes GAPDH and ACTB and 
untreated cells were used as a calibrating condition (ΔΔCt Method). 
 
2.2.4 Electrophysiological measurements 
Dissociated rosette-like structures (differentiation day 7) or NSCs derived from rosettes 
were plated on Multielectrode arrays (MEAs) (1x105 cells/MEA chip) containing complete 
ND medium and differentiated for 3 weeks as described above. At the end of 
differentiation, MEA plates were sealed with a semi-permeable membrane (standard 
MEAs) in a laminar flow hood to keep the cultures sterile for recording of the mean firing 
rate (MFR, number of spikes/min) . Each chip (single well) contains 60 microelectrodes, 
aligned in an 8 x 8 square grid, with the four corners missing. One of the electrodes can 
be replaced by one ground reference, allowing recording from the remaining 59 
electrodes. All data represent the average of at least n=3 biological replicates. The 
measurements were performed with a MEA1060-Inv-BC-amplifier with integrated 
temperature process control adjusted to 37°C and 5% CO2 and data were recorded with 
MC Rack software (Multichannel systems). Peaks from MEA raw data were detected 
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using threshold limit of −4.7 σ, where σ represents the standard deviation of the basal 
noise. From each MEA, the number of spikes/min and bursts/30 min were calculated (a 
burst was considered as a train of at least 2-5 action potentials occurring max every 100 
millisec). Spike number data were normalized with respect to baseline activity for each 
MEA separately. Post-recording data were processed with NeuroExplorer 
(NexTechnologies) and Excel (Microsoft). 
 
2.2.5 Measurements of Nrf2/Luciferase 
Cl27 cells were seeded onto 96-well plates at a density of 50.000 cells/cm2 and treated 
with different concentrations of rotenone (from 1 to 2500 nM), with 100 µM H2O2 (both 
products from Sigma-Aldrich) serving as a positive control, and with DMSO as a negative 
control. The luciferase cell culture lysis reagent was used as a blank. After 24 or 72 hr of 
treatment, the medium was removed and 100 μL of cold PBS was added into each well. 
PBS was removed and cells were lysed in 20 μL of luciferase cell culture lysis reagent at 
room temperature and on a plate shaker for 10 min. 100 μL of Luciferase assay reagent 
was added into each well and determination of the luciferase activity was done following 
manufacturer's protocol (Promega, Madison, WI). The luciferase activity was measured 
by a Tecan plate reader. The data (considering 6 internal replicates per plate, and a total 
of 3 biological replicates) were expressed as fold induction over controls (i.e., either 
untreated cells or undifferentiated NSCs).  
 
2.2.6 Statistical analysis 
Statistical significance was assessed by one-way ANOVA with Dunnett's Multiple 
Comparison Test as Post Test, comparing all columns vs control (Ctr) column using the 
GraphPad Prism 5 software (http://www.graphpad.com/). All data represent the average 
of at least n=3 biological replicates ± standard error mean (S.E.M.). For all graphs, an 
asterisk over a bar indicates a significant difference with the control group, an asterisk 
over a bracket shows a significant difference as indicated. For all graphs, * p < 0.05, ** 
p < 0.01, *** p < 0.001. 
 
 
3 Results 
  
3.1 Effects of rotenone on Cl27 cells (Nrf2/Luciferase reporter 
model) 
 
3.1.1 Neuronal and glial differentiation of Cl27 cells  
First the effects of rotenone on Cl27-Nrf2/luciferase cells (generated by PhenoCell) at 
different stages of differentiation were assessed, to evaluate the activation of the Nrf2 
pathway. As a preliminary step, the neuronal and glial differentiation potential of Cl27 
cells was characterized by analysis of immunocytochemistry and qPCR.  
Cl27 cells expanded efficiently, with a doubling time of ~ 2.5 days. However, some 
pluripotent stem-like cells appeared to be present and grow as tiny colonies that tended 
to expand over time (Figure 2A, B). Upon differentiation, Cl27 cells did not reach an 
advanced stage of differentiation, even when prolonging the differentiation time to 28 
days, as shown by analysis of the NSC marker nestin (Figure 2C), which was expressed 
in nearly all cells after 21 days of differentiation, and analysis of Sox2 (Figure 2H), still 
visible in differentiated cell cultures. Additionally some cells resulted positive for the PSC 
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marker Oct4 (Figure 2H), even after 28 days of differentiation (Figure 2I). Nevertheless, 
despite their poorly differentiated appearance, Cl27 cells expressed classic neuronal 
markers (B-III-tubulin, MAP2, NF200) (Figure 2D-F), and some cells resulted positive for 
GFAP (indicative of astroglia) (Figure 2G).  
qPCR analysis of the NSC-related genes Pax6, Sox1 and Nestin (Figure 2J) and of the 
neuronal gene NCAM1 (Figure 2K) showed no significant variations over time, while the 
neuronal related gene MAP2 (Figure 2K) resulted down-regulated after 21 and 28 days of 
differentiation. On the opposite the synapsis-related genes SYP and MAPT (Figure 2K) 
were significantly upregulated upon differentiation, while GFAP, expressed by glial cells 
did not significantly change and its overall expression resulted very low or absent (Figure 
2K). These results suggest either that the culture conditions and the neuronal 
differentiation protocol recommended by the manufacturer (PhenoCell) are not 
sufficiently optimized (e.g., possible issues with cell plating density) and/or that insertion 
of Nrf2/Luciferase construct could have modified the neuronal differentiation capacity of 
these cells. Additional experiments were done in an effort to optimize the culture 
conditions and improve the differentiation efficiency of Cl27 cells, particularly by (i) 
reducing the cell plating density (from 50.000 to 25.000 cells/cm2), and (ii) by adding 
retinol (vitamin A, contained in the classic B27 supplement), but without significant 
differences (data not shown). 
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Figure 2. Analysis of neuronal and glial differentiation potential of Cl27 cells. (A, B) Cl27 cells could be 
efficiently expanded using manufacturer's protocol; however, PSC-like cells resulted visible already at early 
days of expansion and formed highly dense colonies along the course of time (dashed circles). (C-I) 
Representative images of Cl27 cells differentiated for 21 days and stained for Nestin (red), B-III-tubulin 
(green), NF200 (red), MAP2 (green), GFAP (green), Oct4 (green), Sox2 (red), and counterstained with DAPI. 
Cl27 cells continued to proliferate over time, without generating fully mature neuronal networks. This was also 
confirmed by analysis of NSC markers nestin (C) that resulted expressed in nearly all cells, and Sox2 (H), while 
some cells resulted positive for the PSC marker Oct4 (H, I), even after 28 days of differentiation. Nevertheless, 
despite their not differentiated morphology, Cl27 cells expressed neuronal markers (B-III-tubulin, MAP2, 
NF200), and some cells resulted positive for GFAP (indicative of astroglia). (J, K) qPCR analyses of NSC-related 
genes Pax6, Sox1 and Nestin (J), neuronal related genes NCAM1, MAP2, SYP, MAPT and the glial related gene 
GFAP (K). Total RNA samples were extracted after 0 (NSCs), 7, 14, 21 and 28 days of differentiation and 
processed as described in the Methodological approach section. All values were normalized to β-actin and 
GAPDH and then calibrated to NSCs (undifferentiated cells) (dashed line), ΔΔCt method. All values are shown 
as mean ± S.E.M. of 3 experiments (* p < 0,05, ** p < 0.01).  
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3.1.2 Effect of rotenone on Nrf2 pathway activation in Cl27 cells  
Further analyses were carried out to assess at which stage of neuronal/glial 
differentiation Nrf2 resulted stably expressed in Cl27 cells. To this aim, total RNA were 
extracted from Cl27 cells differentiated for 0 (i.e., NSCs, calibrating condition), 7, 14, 21 
and 28 days, and the expression of the following four Nrf2 target genes was analysed by 
qPCR: NQO1 (NAD(P)H quinone oxidoreductase 1), playing an important role in quinone 
metabolism (Li et al., 2013; Tufekci et al., 2011), SRXN1 (sulfiredoxin 1) that catalyses 
the reversal of overoxidation of peroxiredoxins and deglutathionylation induced by  
oxidative stress (Tufekci et al., 2011; Zhou et al., 2015), HMOX1 (heme oxygenase-1) 
that catalyzes the breakdown of heme into biliverdin, carbon monoxide and iron 
(Kongpetch et al., 2016), and GSR (glutathione reductase) that catalyzes the reduction 
of glutathione disulfide (GSSG) to the sulfhydryl form glutathione (GSH) (Satoh N et al., 
2010). HMOX1 (red bars) resulted significantly upregulated at 14 and 21 days of 
differentiation, NQO1 (yellow bars) expression resulted modestly increased at 28 days of 
differentiation, while the expression of both SRXN1 (blue bars) and GSR (green bars) did 
not change upon differentiation (Figure 3A). These data overall suggest an increase of 
Nrf2 signalling pathway upon differentiation in Cl27 cells. Accordingly, Nrf2 is known to 
contribute to diverse cellular functions including differentiation (Bryan et al., 2013). 
We sought to evaluate the effects of rotenone treatment in Cl27 cells. Cells at three 
differentiation stages (i.e., 5, 12 and 19 DIV) were treated with different concentrations 
of rotenone (i.e., 1, 10, 100, 500, 2500 nM) for either 24 or 72 hr (Figure 3B). The 
viability rate of cells differentiated for 5 days slightly decreased by about 15% upon 72 
hr treatment with 10 nM rotenone (~ IC15) (light grey curve). Cell viability in Cl27 cells 
differentiated for 12 days (dark grey curve) and 19 days (red curve) dropped by nearly 
80-85% with the same concentration (10 nM, ~ IC80-IC85), suggesting that Cl27 cells 
become more sensitive to rotenone treatment upon differentiation (Figure 3C). These 
data are not in line with a previous study showing higher sensitivity to rotenone 
treatment by human NSCs than by their differentiated derivatives, as indicated by 
analysis of ATP depletion (Li J et al., 2015). The effects here described can be explained 
considering the low neuronal/glial differentiation potential of Cl27 cells, which keep 
proliferating even upon mitogen withdrawal and induction of differentiation (Figure 2).   
Moreover, we assessed luciferase activity in Cl27 cells treated with either rotenone 
(using the lowest tested concentration, 1 nM), or H2O2 (100 µM, positive control), 
accounting for solvent DMSO (0.1%) as a negative control. Cells were treated for either 
24 or 72 hr, and then processed for the analysis of luciferase as indicated in the 
Methodological approach. Disappointingly, luciferase/Nrf2 signalling did not increase at 
any differentiation stages and tested time points with both treatments (i.e., rotenone 
and H2O2). On the opposite, 1 nM rotenone appeared to decrease luciferase activity 
particularly at later differentiation stages (i.e., 12 and 19 DIV), and the same effect was 
recorded with H2O2 treatment at 19 days of differentiation. Treatment of Cl27 cells with 
higher concentrations of rotenone (i.e., 10 and 100 nM) at either time points and at all 
tested differentiation stages analogously decreased luciferase activity (data not shown). 
These data further confirm that this Nrf2/luciferase reporter cell model is neither suitable 
as neuronal and glial model, nor can serve to measure Nrf2 activity via luciferase 
quantification.   
For all these reasons we decided to evaluate the effects of rotenone on Nrf2 pathway 
activity using a well-established and optimized cell culture system, the (wild type) 
IMR90-hiPSCs, which can be efficiently differentiated into mixed cultures of neuronal and 
glial cells following previously established protocols (Pistollato et al., 2014; Zagoura et 
al., 2016).  
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Figure 3. Expression of Nrf2 pathway target genes and effects of rotenone on Nrf2 activity in Cl27 
cells. (A) qPCR analyses of the Nrf2-target genes NQO1, SRXN1, HMOX1 and GSR. Total RNA samples were 
extracted after 0 (NSCs), 7, 14, 21 and 28 days of differentiation and processed as described in the 
Methodological approach section. All values were normalized to β-actin and GAPDH and then calibrated to NSCs 
(undifferentiated cells) (dashed line) (ΔΔCt method). (B) Rotenone treatment scheme: Cl27 cells at three 
differentiation stages (i.e., 5, 12 and 19 days of differentiation) were treated with different concentrations of 
rotenone (i.e., 1, 10, 100, 500, 2500 nM) for either 24 or 72 hr. Analysis of luciferase (indicative of Nrf2 
expression) was done at both time points (i.e., 24 hr and 72 hr), while the Alamar blue assay (resazurin) was 
performed after 72 hr treatment to evaluate possible cytotoxic effects. H2O2 (100 µM) was used as a positive 
control, and solvent DMSO (0.1%) as a negative control. (C) Alamar blue assay (resazurin): cell viability in 
Cl27 cells differentiated for 5 days slightly decreased (by about 15%) upon treatment with 10 nM rotenone (~ 
IC15) (light grey curve); in Cl27 cells differentiated for 12 days (dark grey curve) and 19 days (red curve) 
viability dropped by nearly 80-85% with the same concentration (10 nM, ~ IC80-IC85), indicating that Cl27 cells 
result more sensitive to rotenone treatment upon differentiation. (D) Analysis of luciferase: Cl27 cells were 
treated with either 1 nM rotenone, or H2O2 (100 µM, positive control), accounting for solvent DMSO (0.1%) as 
a negative control. After either 24 or 72 hr, cells were processed for luciferase analysis as indicated in the 
Methodological approach section. Luciferase/Nrf2 signalling did not increase at any differentiation stages and 
time points with both treatments (rotenone and H2O2). On the opposite, 1 nM rotenone appeared to decrease 
luciferase signalling particularly at later differentiation stages (12 and 19 days of differentiation), and the same 
effect was recorded for H2O2 treatment at 19 days of differentiation (RLU, relative light unit). Values are shown 
as mean ± S.E.M. of three biological replicates (* p < 0,05, ** p < 0.01, *** p < 0.001). 
 
 
3.2 Effects of Rotenone on Nrf2 pathway activation in IMR90-
hiPSC-derived neuronal model (wild type) 
 
3.2.1 Neuronal and glial differentiation of IMR90-hiPSCs  
IMR90-hiPSCs were directly differentiated into mixed cultures of neuronal and glial cells 
for 28 days (Figure 4, upper part). In parallel, a protocol for rosette-derived neural stem 
cell (NSC) expansion and cryopreservation was developed. NSCs could be further 
differentiated into neurons and glial cells for 21 days (Figure 4, lower part). 
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Figure 4. Schematic representation of the neuronal differentiation protocol. (Upper part) IMR90-hiPSC 
colonies (here stained for Oct4, red) were cut into fragments to form embryoid bodies (EBs, phase bright 
picture). EBs were plated onto laminin-coated dishes and cultured in the presence of neuroepithelial induction 
(NRI) medium to generate rosettes (neuroectodermal derivatives, here stained for B-III-tubulin (red) and 
Nestin (green)), which were further differentiated into mature neuronal (NF200, red) and glial (GFAP, green) 
cells in the presence of neuronal differentiation (ND) medium. (Lower part) in parallel, a protocol for the 
expansion and cryopreservation of rosette-derived neural stem cells (NSCs) was developed. NSCs (nestin, red) 
were expanded in the presence of neural induction (NI) medium or directly differentiated in the presence of ND 
medium to form mixed neuronal (NF200, green) and glial (GFAP, red) cultures (all cells were counterstained 
with DAPI). More detailed information about the culture protocols and the characterization of the cellular model 
used in this study is available at: (Zagoura et al., 2016) and at https://ecvam-
dbalm.jrc.ec.europa.eu/methods-and-protocols/protocol/standard-operating-procedure-for-differentiation-of-
human-induced-pluripotent-stem-cells-into-post-mitotic-neurons-and-glial-cells-%28mixed-culture%29-
protocol-no.-165/key/p_1570  and https://ecvam-dbalm.jrc.ec.europa.eu/methods-and-
protocols/protocol/standard-operating-procedure-for-expansion-of-rosette-derived-neural-stem-cells-protocol-
no.-166/key/p_1571  
 
 
Differentiated neuronal-like cells derived from IMR90-hiPSCs expressed high level of the 
major neuronal cytoskeleton protein, neurofilament 200 (NF200) and about 25-30% of 
the cells were positive for the glial fibrillary acidic protein (GFAP), marker of astroglia 
(Zagoura et al., 2016). Similar results were obtained by analyzing neuronal population 
obtained by expanding rosette-derived NSCs and their further differentiation into 
neurons (Zagoura et al., 2016). We also found that ~ 25-30% of cells still retained the 
expression of nestin after differentiation (Zagoura et al., 2016). Furthermore, 
dopaminergic neurons represented ~ 13-20% of total cell number, GABAergic neurons ~ 
15-20%, and glutamatergic neurons ~ 35-42%, as shown by IC analyses of tyrosine 
hydroxylase (TH), gamma-aminobutyric acid (GABA), and Vesicular Glutamate 
Transporter 1 (VGlut1) respectively (not shown).  
Additionally, differentiated cultures derived from hiPSCs showed neuronal spontaneous 
electrical activity, with a mean firing rate (MFR) of ~ 293 spikes/minute, and neurons 
derived from expanded NSCs yielded similar results, with a MFR of ~ 239 spikes/minute 
(not shown). More detailed information about the culture protocols and the 
characterization of the cellular model used in this study is described in (Zagoura et al., 
2016).     
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3.2.2 Effect of rotenone on Nrf2 pathway in IMR90-hiPSCs 
Rotenone causes oxidative stress by triggering the translocation of Nrf2 from the 
cytoplasm into the nucleus and Nrf2-ARE target gene transcriptional activation (Tufekci 
et al. 2011). To evaluate rotenone effects on Nrf2 activation, IMR90-hiPSC-derived 
neurons and glial cells were exposed to different concentrations of rotenone (1, 10 and 
100 nM) for 24 hr (Figure 5A). These concentrations were established according to 
previous studies (Kovac et al., 2015; Lee et al., 2003). Rotenone did not induce 
cytotoxicity at these tested concentrations, as shown by morphological analysis and 
quantification of live DAPI+ cell nuclei (Figure 5C).  
Induction of Nrf2 nuclear translocation was observed especially after exposing the cells 
to the highest concentration of rotenone (100 nM) (Figure 5B, D). In parallel, cells 
exposed to 100 nM rotenone showed a significant decrease of cytoplasmic Keap1 (Kelch-
like ECH-associated protein 1) (Figure 5E), a key Nrf2 repressor (Bryan et al., 2013).  
Moreover, exposure to 10 and 100 nM rotenone induced a concentration-dependent 
increase of the Nrf2-target enzymes NQO1 and SRXN1, as shown by immuno-
cytochemical analysis (Figure 5F).  
 
 
Figure 5. Effects of rotenone on Nrf2 nuclear translocation, Keap1 and antioxidant enzyme levels in 
IMR90-hiPSCs derived neurons. (A) Representative phase bright images of IMR90-hiPSC-derived neurons 
treated with 1, 10, 100 nM rotenone for 24 hr. (B) Representative IC images of Nrf2 protein localization 
(green). (C) Quantification of live DAPI+ cells (i.e., non-pyknotic nuclei) upon 24 hr exposure to rotenone (1, 
10, 100 nM) and normalized to untreated cells (Ctr). (D) Nrf2 protein nuclear translocation (i.e., 
nuclear/cytoplasmic ratios) after 24 hr of exposure to rotenone assessed by measurements of fluorescence 
intensity using HCI analysis. (E) Quantification of cytoplasmic Keap1 protein levels upon rotenone treatment, 
assessed by HCI analysis. (F) Quantification of NAD(P)H Quinone Oxidoreductase 1 (NQO1) and Sulfiredoxin1 
(SRXN1) by means of IC and HCI upon 24 hr treatment with rotenone. All values are shown as mean ± S.E.M. 
of three biological replicates (* p<0,05, ** p<0.01). 
 
 
3.2.3 Effect of rotenone on IMR90-hiPSC-derived glial cells and 
dopaminergic neurons  
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We further analysed whether rotenone had any effects on the proportion of nestin+, 
MAP2+ and GFAP+ cells. We found that rotenone increased the percentage of astroglial 
cells in a concentration-dependent manner, promoting respectively a ~ 46%, ~ 57% and 
~ 99% increase in the number of GFAP+ cells compared to control (Figure 6A, C), which 
was also confirmed by qPCR analysis of GFAP gene expression (not shown). On the 
contrary, rotenone did not affect the proportions of both nestin+ (NSCs) and MAP2+ cells 
(neurons) (Figure 6C), which was confirmed also by qPCR analysis (not shown). 
Moreover, we found that the number of dopaminergic TH+ neurons was significantly 
decreased by rotenone treatment, particularly at higher concentrations (i.e., 10 nM and 
100 nM) (Figure 6B, D). This is line with previous studies describing a rotenone-
dependent and selective dopaminergic neuronal cell death, as shown both in vivo 
(Cannon et al., 2009; Sherer et al., 2003) and in vitro (Testa et al. 2005). Analysis of 
GABAergic (GABA+) and glutamatergic (VGlut1+) neurons showed no significant changes 
upon rotenone treatment (Figure 6D).  
Gene expression analysis of GABAergic (GABRA1 and GABRA3), glutamatergic (GRIA1 
and GAP43) and dopaminergic (TH and NR4A2) neuronal-related genes revealed no 
significant variations for GABRA1, GABRA3 and GRIA1 genes, while down-regulation of 
both GAP43 and NR4A2 (Nurr1) was observed upon rotenone treatment (Figure 6E). 
Opposite to protein level, TH gene expression resulted significantly increased by 
rotenone, especially at the highest concentration (100 nM, Figure 6E). TH gene up-
regulation by rotenone was also described in PC12 cells (Hohler et al., 1999). This up-
regulation could be associated with compensatory mechanisms induced in the surviving 
cells to recover the reduction of TH protein elicited by rotenone. 
 
 
Figure 6. Effects of rotenone on IMR90-hiPSC-derived glial cells and on dopaminergic neurons. (A, 
B) Representative pictures of GFAP+ cells (red, A), and dopaminergic TH+ neurons (green, B), with 40X 
magnification insets, left untreated and upon exposure to different concentrations of rotenone (1 nM, 10 nM 
and 100 nM) for 24 hr. (C, D) Quantification of nestin+, MAP2+, GFAP+ cells (C), and of GABA+, VGlut1+ and 
TH+ neuronal cells (D) by HCI using the Array Scan vTi platform. (E) qPCR analyses of GRIA1 (Glutamate 
Ionotropic Receptor AMPA Type Subunit 1), GAP43 (Growth Associated Protein 43), GABRA1 (Gamma-
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Aminobutyric Acid Type A Receptor Alpha1 Subunit), GABRA3 (Gamma-Aminobutyric Acid Type A Receptor 
Alpha3 Subunit), TH (Tyrosine Hydroxylase), NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2). All 
values were normalized to β-actin and GAPDH and then calibrated to untreated cells (Ctr, dashed line) (ΔΔCt 
method). All values are shown as mean ± S.E.M. of three biological replicates (* p<0,05, ** p<0.01, *** 
p<0.001). 
 
 
4 Discussion and conclusions 
This technical report describes the effects elicited by rotenone on the Nrf2 pathway 
activation in two models of hiPSC-derived neuronal cultures. However, the results 
obtained with the Nrf2/luciferase reporter model (named Cl27) have not allowed us to 
draw clear conclusions about the effects of rotenone on Nrf2 pathway activation. Cl27 
cells kept proliferating even upon mitogen (bFGF and EGF) withdrawal and induction of 
differentiation, and did not form mature neuronal networks. Additionally, treating Cl27 
cells with non-cytotoxic concentration of rotenone or with hydrogen peroxide did not 
increase luciferase activity. These issues could be due to several factors, such as (i) the 
culture conditions and the neuronal differentiation protocol indicated by the 
manufacturer (PhenoCell) require further optimization, and/or (ii) the insertion of the 
Nrf2/luciferase construct has affected the neuronal differentiation capacity of these cells. 
Considering these intrinsic limitations, the effects of rotenone on Nrf2 pathway activity 
were further investigated using a well-established and optimized cell culture system, the 
IMR90-hiPSCs (wild type). These cells can be efficiently differentiated into mixed 
cultures of neuronal and glial cells following previously established and optimized 
protocols (Pistollato et al., 2014; Zagoura et al., 2016).  
Differentiated cultures derived from IMR90-hiPSCs or from expanded rosette-derived 
NSCs were composed of neurons expressing classical neuronal proteins (e.g., NF200 and 
MAP2) and astrocytes. Astrocytes play an important role in the regulation of oxidative 
stress defence mechanisms, extracellular glutamate uptake, ions balance, and function 
of neuronal networks (Barker and Ullian, 2008; Bell et al., 2011; Figley and Stroman, 
2011; Santello and Volterra, 2009). Additionally, the adopted neuronal differentiation 
protocol allowed the formation of different neuronal subtypes (i.e., GABAergic, 
glutamatergic and dopaminergic neurons), and these neuronal derivatives resulted to be 
electrically active, as shown by MEA analysis (Zagoura et al., 2016).   
 
Oxidative stress is one of the early effects observed in neuronal cultures exposed to 
different classes of chemicals, such as rotenone, a known inhibitor of mitochondrial 
respiration chain (Peng et al., 2013; Satoh et al., 2009). In an effort to maintain 
homeostasis, neuronal and glial cells respond to chemical insults by activating signalling 
pathways, such as Nrf2. Nrf2 is known to play a cytoprotective, antioxidant and anti-
inflammatory role (Lee et al., 2003; Shih et al., 2005; Tufekci et al., 2011), and is 
critical in the regulation of cellular defence mechanisms in many body tissues, including 
the brain (Lee et al., 2003; Shih et al., 2005). Under physiological conditions Nrf2 
protein levels are kept low in the cytoplasm due to the rapid proteasome-mediated 
degradation controlled by the Keap1 protein, an Nrf2-specific ligase adaptor protein 
(Gorrini et al., 2013; Hartikainen et al., 2012; Harvey et al., 2009; Kansanen et al., 
2013). In response to various triggers of oxidative stress, Nrf2 dissociates from Keap1 
and translocates into the nucleus (Kovac et al., 2015; Tufekci et al., 2011).  
In this report we showed that an acute exposure (24 hr) to rotenone triggered the 
activation of Nrf2 pathway in IMR90-hiPSC-derived neuronal and glial cultures. In 
particular, rotenone induced Nrf2 nuclear translocation and a decrease of cytoplasmic 
Keap1 protein. Moreover, rotenone increased in a concentration-dependent manner 
NQO1 and SRXN1 protein levels, two enzymes whose expression is controlled by Nrf2 
(Itoh et al., 1997; Li et al., 2014), which confirmed the activation of the Nrf2 pathway. 
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These data indicate that rotenone, by inducing the inhibition of complex I, triggers ROS 
production and Nrf2 pathway activation (Barrientos and Moraes, 1999). Both NQO1 and 
SRXN1 protect cells against these effects, as NQO1 catalyzes the reduction of highly 
reactive quinones, while SRXN1 reduces cysteine-sulfinic acid formed under exposure to 
oxidants in peroxiredoxins (Ma, 2013).  
Additionally, rotenone elicited a dose-dependent increase of GFAP gene expression and 
protein level, indicative of astrocyte activation (Bal-Price et al., 2010; Cabezas et al., 
2012; Swarnkar et al., 2012). Astrocytes are known to respond to different neurological 
insults (e.g., oxidative stress) by undergoing reactive astrogliosis (Radad et al., 2008; 
Swarnkar et al., 2012), and astrocytes play a major role in Nrf2-ARE mediated 
neuroprotection (Johnson et al., 2008). 
Importantly, rotenone promoted a decrease in the number of dopaminergic (TH+) cells. 
This is in line with previous in vitro and in vivo studies that have shown that rotenone 
causes a specific dopaminergic neuronal cell death (Testa et al., 2005; Cannon et al., 
2009; Sherer et al., 2003). Dopaminergic neurons are particularly sensitive to several 
stressors, including oxidative stress (Fujita et al., 2014).  
Altogether these data indicate that hiPSC-derived neuronal and glial culture models 
could be valuable to study the neurotoxic effects of chemicals that elicit oxidative stress 
and activation of the Nrf2 pathway. Oxidative stress is a common key event in various 
Adverse Outcome Pathways (AOPs) relevant to developmental and adult neurotoxicity 
(Bal-Price et al., 2015b). Defining key events in AOPs (e.g., Nrf2 pathway activation), 
could allow assay development for the creation of integrated testing strategies (Bal-Price 
et al., 2015a), such as AOP-informed IATA (Integrated Approaches to Testing and 
Assessment) for neurotoxicity testing (Tollefsen et al., 2014), providing mechanistic 
knowledge suitable to facilitate regulatory decision making process. 
The data on the effects of rotenone on the IMR90-hiPSC-neuronal model described in the 
this technical report have been published in: Zagoura D, Canovas-Jorda D, Pistollato F, 
Bremer-Hoffmann S, Bal-Price A. 2016. Evaluation of the rotenone-induced activation of 
the Nrf2 pathway in a neuronal model derived from human induced pluripotent stem 
cells. Neurochem Int. Sep 9. pii: S0197-0186(16)30284-4. 
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